# US 2019/0315692 A1 · Antagonists of human integrin (alpha4)(beta7)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315692 A1
- Document ID: US20190315692A1
- Status: Published application
- Kind: A1
- Application number: 16/382,512
- Filed: 2019-04-12
- Published: 2019-10-17
- Earliest claimed: 2018-04-12
- Assignees: Morphic Therapeutic, Inc.
- Applicants: Morphic Therapeutic, Inc.
- Inventors: Matthew G. Bursavich; Dawn M. Troast; Bryce A. Harrison; Blaise S. Lippa; Bruce N. Rogers; Kyle D. Konze; Aleksey I. Gerasyuto; Tyler Day; Fu-Yang Lin; Kristopher N. Hahn; Mats A. Svensson; Byungchan Kim; Cheng Zhong; Alexey A. Lugovskoy; Brian Sosa
- Web page: https://patentgrep.com/patent/US20190315692A1

## CPC

- C07D 213/64: attached in position 2 or 6
- C07D 205/08: with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D 237/32: with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- C07D 239/90: with acyclic radicals attached in position 2 or 3
- C07D 241/18: Oxygen or sulfur atoms
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.

## Claims

### Claim 1

A compound represented by formula (I):
wherein:
R1 is H, alkyl, alkylene-cycloalkyl, heterocyclyl, alkylene-O-alkyl, aryl, heteroaryl, or alkylene-CF3;
R2 is heterocyclyl;
R3 is, or;
R4 is H, or (C1-C6)-alkyl;
Ra is H, alkyl, cycloalkyl, CN, or —O-alkyl;
Rb is H, alkyl, aryl, heteroaryl, heterocylcyl, —O-cycloalkyl, —O-aryl, or —O— heterocyclyl;
Rc is H, alkyl, cycloalkyl, hetrocyclyl, or alkylene-CF3;
Rd is aryl, heteroaryl, heterocyclyl, —O-cycloalkyl, —O-aryl, or —O-heterocyclyl; and
Re is aryl, heteroaryl, or heterocyclyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is alkyl.

### Claim at position 3

3-25. (canceled)

### Claim 26 (depends on 1)

The compound of claim 1, wherein R2 is selected from

### Claim 27 (depends on 1)

The compound of claim 1, wherein R2 is selected from

### Claim 28 (depends on 1)

The compound of claim 1, wherein R3 is

### Claim 29 (depends on 28)

The compound of claim 28, wherein Ra is methyl, cyclopropyl, CN, or —OMe.

### Claim 30 (depends on 28)

The compound of claim 28, wherein Rb is alkyl, aryl, heterocyclyl, heteroaryl, —O-cycloalkyl, —O-aryl, or —O-heteroaryl.

### Claim at position 9

-37. (canceled)

### Claim 38 (depends on 28)

The compound of claim 28, wherein Rb is selected from

### Claim at position 11

-41. (canceled)

### Claim 42 (depends on 28)

The compound of claim 28, wherein Rb is selected from

### Claim 43 (depends on 28)

The compound of claim 28, wherein Rb is selected from

### Claim at position 14

-47. (canceled)

### Claim 48 (depends on 1)

The compound of claim 1, wherein R3 is

### Claim 49 (depends on 48)

The compound of claim 48, wherein Rc is alkyl, cycloalkyl, (heterocyclyl)akyl, halogen, or CF3.

### Claim at position 17

-51. (canceled)

### Claim 52 (depends on 1)

The compound of claim 1, wherein R3 is

### Claim 53 (depends on 52)

The compound of claim 52, wherein Rd is aryl, heteroaryl, or heterocyclyl.

### Claim at position 20

-56. (canceled)

### Claim 57 (depends on 53)

The compound of claim 53, wherein Rd is selected from

### Claim at position 22

-61. (canceled)

### Claim 62 (depends on 53)

The compound of claim 53, wherein Rd is

### Claim 63

(canceled)

### Claim 64 (depends on 53)

The compound of claim 53, wherein Rd is selected from

### Claim 65 (depends on 1)

The compound of claim 1

### Claim at position 27

-69. (canceled)

### Claim 70 (depends on 65)

The compound of claim 65, wherein Re is or

### Claim at position 29

-73. (canceled)

### Claim 74 (depends on 65)

The compound of claim 65, wherein Re is

### Claim 75 (depends on 1)

The compound of claim 1, wherein R4 is H.

### Claim 76 (depends on 1)

The compound of claim 1, wherein R4 is (C1-C6)-alkyl.

### Claim 77

(canceled)

### Claim 78 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 79 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 80 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 81 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 82 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 83 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 84 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 85 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 86 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 87 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 88 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 89 (depends on 1)

The compound of claim 1, wherein the compound is selected from group consisting of:

### Claim 90 (depends on 1)

The compound of claim 1, wherein the compound is selected from group consisting of:

### Claim 91

(canceled)

### Claim 92 (depends on 1)

A method of treating a disease or condition selected from the group consisting of inflammatory bowel disease, ileoanal anastomosis, eosinophilic esophagitis, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, graft versus host disease, a chronic inflammatory disease of the lung, HIV, and hematological tumor, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of aneasef claim 1.

### Claim at position 49

-104. (canceled)
